Technology Listings

P-selectin Inhibitor for the Treatment of Sickle Cell Disease


A glycopeptide inhibitor of p-selectin for the treatment of sickle cell disease.

Key Benefits
  • Blocks the activity of P-selectin with nM affinity.
  • Potential treatment forvaso-occlusive crisis associated with sickle cell disease.
  • Inhibits the earliest stage of leukocyte activation helping to prevent immune response.
Market Summary

Sickle cell anemia, a serious disorder in which the body makes sickle-shaped red blood cells, affects an estimated 95,000 Americans and a majority of these are African Americans. About two million Americans or 1 in 12 of African Americans have the sickle cell trait. The most common clinical manifestation of sickle cell disease is vaso-occlusive crisis, which results in an average of 2.5 hospital visits per year for sickle cell patients in the U.S. Current treatments for vaso-occlusive crisis, such as opioids and rehydration, are primarily focused only the management of symptoms.

Technical Summary

P-selectin is a constitutively expressed carbohydrate-binding protein that helps activate leukocytes to initiate the inflammatory response in mammals. The best characterized ligand for P-selectin is called P-selectin glycoprotein ligand-1 (PSGL-1) which is expressed on the surface membranes of all leukocytes. PSGL-1 supports leukocyte recruitment in both innate and adaptive arms of the immune response. Because PSGL-1 plays an important role invascular endothelial signaling, a PSGL-1 mimetic with the ability to block the activity of P-selectin has the potential to treat multiple indications, such as sickle cell anemia vaso-occlusive crisis, vascular inflammation, and thrombosis.

Developmental Stage

In vivo studies in mice show efficient blockade of P-selectin-dependent binding of leukocytes to the activated endothelium of blood vessels.

View our feature innovation

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Nationalized PCT - Foreign Canada 2,914,470   12/2/2015     Pending
Nationalized PCT - United States United States 14/895,606 10,253,071 12/3/2015 4/9/2019 6/12/2034 Issued
Nationalized PCT - Foreign EP 14806846.3   12/11/2015     Pending
Divisional United States 16/352,585 3/13/2019     Pending
Tech ID: 13089
Published: 12/4/2013

John Nicosia
Licensing Associate
Emory University

Richard Cummings
Elliot Chaikof
Venkata Krishnamurthy
Mohammed Sardar

Hematology/Blood Products
Small Molecule